Skip to main content
Contact Us
Subscribe
E-Edition
68°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novocure Ltd Ord Sh
(NQ:
NVCR
)
17.44
-0.21 (-1.19%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novocure Ltd Ord Sh
< Previous
1
2
3
4
5
6
7
Next >
Novocure Appoints Christoph Brackmann as Chief Financial Officer
October 30, 2024
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2024 Financial Results
October 30, 2024
From
Novocure
Via
Business Wire
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 15, 2024
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2024 Financial Results
October 01, 2024
From
Novocure
Via
Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
January 18, 2024
Via
Investor Brand Network
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
September 09, 2024
From
Novocure
Via
Business Wire
Novocure Announces Planned CEO Transition
September 03, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
August 28, 2024
From
Novocure
Via
Business Wire
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
August 14, 2024
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2024 Financial Results
July 25, 2024
From
Novocure
Via
Business Wire
Novocure to Report Second Quarter 2024 Financial Results
July 01, 2024
From
Novocure
Via
Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
June 03, 2024
From
Novocure
Via
Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
May 02, 2024
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2024 Financial Results
May 02, 2024
From
Novocure
Via
Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
April 24, 2024
From
Novocure
Via
Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2024 Financial Results
April 01, 2024
From
Novocure
Via
Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Novocure
Via
Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
March 11, 2024
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
February 22, 2024
From
Novocure
Via
Business Wire
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
January 18, 2024
From
Novocure
Via
Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
January 09, 2024
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
January 08, 2024
From
Novocure
Via
Business Wire
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
January 04, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Novocure
Via
Business Wire
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
November 28, 2023
From
Novocure
Via
Business Wire
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
November 21, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
November 10, 2023
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2023 Financial Results
October 26, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
October 15, 2023
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
